Harvard Bioscience (HBIO) Shares Outstanding (Weighted Average) (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $4.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $4.5 million, up 1.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (up 1.43% YoY), and the FY2025 annual result was $4.4 million, down 89.8% from the prior year.
• Shares Outstanding (Weighted Average) grew to $4.5 million in Q1 2026 per HBIO's latest filing, from $4.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $44.3 million in Q3 2025 and troughed at $4.4 million in Q1 2025.
• A 5-year average of $35.9 million and a median of $42.3 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) surged 102763.04% in 2022, then slumped 89.84% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $41.4 million in 2022, then grew by 2.43% to $42.4 million in 2023, then grew by 2.64% to $43.5 million in 2024, then plunged by 89.8% to $4.4 million in 2025, then gained by 0.77% to $4.5 million in 2026.
• Business Quant data shows HBIO's Shares Outstanding (Weighted Average) at $4.5 million in Q1 2026, $4.4 million in Q4 2025, and $44.3 million in Q3 2025.